Business Context and Reporting Period
Company: ICU Medical, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2003
Business Overview: ICU Medical develops, manufactures, and sells disposable medical connection products, primarily the CLAVE needleless I.V. connection system and custom I.V. systems. In late 2002, the company acquired Bio-Plexus, Inc., adding blood collection needles (Punctur-Guard) to its portfolio.
Key Financial Metrics
| Metric (in thousands) | Q1 2003 | Q1 2002 |
|---|---|---|
| Total Revenue | $30,776 | $20,905 |
| Net Sales | $28,736 | $20,905 |
| Gross Profit | $17,752 | $12,349 |
| Net Income | $7,070 | $4,523 |
| Diluted EPS | $0.46 | $0.30 |
| Cash from Operations | $2,995 | $7,615 |
| Cash & Liquid Investments | $78,854 | $88,465 |
| Working Capital | $99,886 | $102,564 |
Margins: Gross margin on Net Sales was 55% in Q1 2003, down from 59% in Q1 2002. Operating income margin was 36% of total revenue.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 47% ($9.9 million) year-over-year. This was driven by a 41% increase in CLAVE sales to Abbott, a 62% increase in custom I.V. systems, and the inclusion of Bio-Plexus revenues ($1.8 million).
- Customer Concentration: Abbott Laboratories accounted for 68% of net revenues in Q1 2003 (up from 67% in Q1 2002). Sales to B. Braun Medical Inc. dropped significantly as the CLAVE distribution agreement was terminated in December 2002.
- Profitability: Net income rose 56% to $7.1 million. However, gross margins compressed slightly due to the inclusion of lower-margin Bio-Plexus products and non-recurring production expenses.
- Liquidity: Cash and liquid investments decreased by $9.6 million. This reduction was primarily due to $8.6 million spent on treasury stock repurchases and $3.0 million in capital expenditures.
- Accounts Receivable: Increased significantly to $27.0 million (from $16.6 million) due to a high volume of shipments in late March 2003 where payment was due after the quarter-end.
Guidance, Outlook, and Risks
- Outlook: Management expects continued significant growth in CLAVE unit and dollar sales in 2003, despite the loss of B. Braun as a direct customer. They anticipate gross margins for the full year 2003 to be equal to or slightly lower than the 57% recorded in 2002.
- Capital Expenditures: Estimated at approximately $12 million for 2003, including a $7.2 million expansion in Mexico and investments in automated assembly equipment.
- Product Pipeline: Plans to launch an infusion device using Punctur-Guard technology in Q2 2003 and apply for FDA approval for a new I.V. connector in the second half of 2003.
- Risks:
- Customer Dependence: Heavy reliance on Abbott (68% of revenue) and the potential loss of contracts with major buying organizations.
- Competition: Price erosion due to competitors developing similar needleless connectors; the company is reducing prices to maintain market share.
- Legal: Ongoing patent litigation against B. Braun Medical, Inc. regarding the UltraSite connector.
- Regulatory: Uncertainty regarding FDA approval for new products.
- Dividends: The company is considering the payment of a dividend, though no decision has been made.
Investor Verification Checklist
- Abbott Contract Stability: Verify the status and terms of the Abbott Agreements extending to 2009, given the 68% revenue concentration.
- B. Braun Litigation Outcome: Monitor the patent infringement lawsuit against B. Braun for potential damages or injunctions.
- Margin Sustainability: Assess whether the 55% gross margin can be sustained or improved as Bio-Plexus integration continues and price pressures mount.
- Capital Allocation: Review the impact of the $8.6 million stock buyback on future liquidity and capital expenditure plans.
- Receivables Quality: Monitor the collection of the $27 million accounts receivable balance, particularly the portion shipped in late March.